Skip to main content
Erschienen in: Journal of Diabetes & Metabolic Disorders 1/2018

26.03.2018 | Research Article

Genotype and phenotype of salt-stimulated paraoxonase 1 (PON1) is associated with atherogenic indices in type 2 diabetes

verfasst von: Durdi Qujeq, Abdolkarim Mahrooz, Ahad Alizadeh, Parisa Masoumi, Saleh Annemohammadzadeh, Ruzbeh Boorank

Erschienen in: Journal of Diabetes & Metabolic Disorders | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Paraoxonase 1 (PON1) and lipid abnormalities contribute to the development of cardiovascular disease, which is the principal cause of mortality in patients with type 2 diabetes (T2D). Data are not available on the potential association between salt-stimulated activity of PON1 (PON1-salt) and the atherogenic indices in T2D, therefore, we focused on these associations and evaluated whether the functional variants PON1-Q192R and PON1-L55M influence the associations.

Methods

Paraoxonase activity (PON1-para), arylesterase activity (PON1-aryl) and salt-stimulated activity (PON1-salt) were measured by spectrophotometric assays. The atherogenic index of plasma (AIP) was calculated from the log (TG/HDL-C). The genetic analyses were made by the restricted fragment length polymorphism after PCR amplification.

Results

We observed that PON1-salt was negatively correlated with total cholesterol (TC)/HDL-C (r = −0.441,p = 0.006), LDL-C/HDL-C (r = −0.415, p = 0.011), and AIP (r = −0.422, p = 0.009). Correlations between PON1-salt and all three atherogenic indices were significantly affected by PON1-L55M and PON1-Q192R. Linear regression showed that AIP (p = 0.002), LDL-C/HDL-C (p = 0.005), and TC/HDL-C (p = 0.002) were independently associated with PON1-salt. Based on Ridge regression, the standardized coefficients −0.358, −0.297, and − 0.044 were obtained for AIP, LDL-C/HDL-C, and TC/HDL-C, respectively, and this shows that AIP could have more negative effect on PON1-salt than the others.

Conclusions

The decreased PON1-salt may be considered as a risk factor for atherosclerosis in T2D, therefore, understanding the associations between PON1-salt as an important although neglected property and atherogenic indices may be valuable in T2D. Accordingly, detection of PON1-salt status (phenotype and genotype) together with the atherogenic indices particularly AIP could be beneficial in identifying the increased atherogenicity in T2D.
Literatur
1.
Zurück zum Zitat Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.CrossRefPubMed Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.CrossRefPubMed
2.
Zurück zum Zitat Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567:12–21.CrossRefPubMedPubMedCentral Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567:12–21.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Mahrooz A. Pharmacological interactions of paraoxonase 1 (PON1): A HDL-bound antiatherogenic enzyme. Curr Clin Pharmacol. 2016;11:259–64.CrossRefPubMed Mahrooz A. Pharmacological interactions of paraoxonase 1 (PON1): A HDL-bound antiatherogenic enzyme. Curr Clin Pharmacol. 2016;11:259–64.CrossRefPubMed
4.
Zurück zum Zitat Kim DS, Marsillach J, Furlong CE, Jarvik GP. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics. 2013;14:1495–515.CrossRefPubMedPubMedCentral Kim DS, Marsillach J, Furlong CE, Jarvik GP. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics. 2013;14:1495–515.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Hegele RA, Connelly PW, Scherer SW, Hanley AJG, Harris SB, Tsui LC, et al. Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet. 1997;350:785.CrossRefPubMed Hegele RA, Connelly PW, Scherer SW, Hanley AJG, Harris SB, Tsui LC, et al. Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet. 1997;350:785.CrossRefPubMed
6.
Zurück zum Zitat Koren-Gluzer M, Aviram M, Meilin E, Hayek T. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release. Atherosclerosis. 2011;219:510–8.CrossRefPubMed Koren-Gluzer M, Aviram M, Meilin E, Hayek T. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release. Atherosclerosis. 2011;219:510–8.CrossRefPubMed
7.
Zurück zum Zitat Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, et al. Association between PON1 polymorphisms, PON activity and diabetes complications. J Diabetes Complicat. 2006;20:322–8.CrossRefPubMed Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, et al. Association between PON1 polymorphisms, PON activity and diabetes complications. J Diabetes Complicat. 2006;20:322–8.CrossRefPubMed
8.
Zurück zum Zitat Aubo C, Senti M, Marrugat J, et al. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. Eur Heart J. 2000;21:33–8.CrossRefPubMed Aubo C, Senti M, Marrugat J, et al. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. Eur Heart J. 2000;21:33–8.CrossRefPubMed
9.
Zurück zum Zitat Li J, Wang X, Huo Y, Niu T, Chen C, Zhu G, et al. PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. Genet Med. 2005;7:58–63.CrossRefPubMed Li J, Wang X, Huo Y, Niu T, Chen C, Zhu G, et al. PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. Genet Med. 2005;7:58–63.CrossRefPubMed
10.
Zurück zum Zitat Mahrooz A, Alizadeh A, Gohari G. The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke: The role of activity-determined PON1 192Q/R phenotypes. J Neurol Sci. 2014;338:197–202.CrossRefPubMed Mahrooz A, Alizadeh A, Gohari G. The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke: The role of activity-determined PON1 192Q/R phenotypes. J Neurol Sci. 2014;338:197–202.CrossRefPubMed
11.
Zurück zum Zitat Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–34.CrossRefPubMed Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–34.CrossRefPubMed
12.
Zurück zum Zitat Irie Y, Katakami N, Kaneto H, Nishio M, Kasami R, Sakamoto K, et al. The utility of carotid ultrasonography in identifying severe coronary artery disease in asymptomatic type 2 diabetic patients without history of coronary artery disease. Diabetes Care. 2013;36:1327–34.CrossRefPubMedPubMedCentral Irie Y, Katakami N, Kaneto H, Nishio M, Kasami R, Sakamoto K, et al. The utility of carotid ultrasonography in identifying severe coronary artery disease in asymptomatic type 2 diabetic patients without history of coronary artery disease. Diabetes Care. 2013;36:1327–34.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005;31:429–39.CrossRefPubMed Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005;31:429–39.CrossRefPubMed
14.
Zurück zum Zitat Brown WV, Clark L, Falko JM, Guyton JR, Rees TJ, Schonfeld G, et al. Optimal management of lipids in diabetes and metabolic syndrome. J Clin Lipidol. 2008;2:335–42.CrossRefPubMed Brown WV, Clark L, Falko JM, Guyton JR, Rees TJ, Schonfeld G, et al. Optimal management of lipids in diabetes and metabolic syndrome. J Clin Lipidol. 2008;2:335–42.CrossRefPubMed
15.
Zurück zum Zitat Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004;50:2316–22.CrossRefPubMed Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004;50:2316–22.CrossRefPubMed
16.
Zurück zum Zitat Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001;34:583–8.CrossRefPubMed Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001;34:583–8.CrossRefPubMed
17.
Zurück zum Zitat Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50:1184–8.CrossRefPubMed Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50:1184–8.CrossRefPubMed
18.
Zurück zum Zitat Mahrooz A, Gohari G, Hashemi MB, Zargari M, Musavi H, Abedini M, et al. R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke. Mol Biol Rep. 2012;39:11177–85.CrossRefPubMed Mahrooz A, Gohari G, Hashemi MB, Zargari M, Musavi H, Abedini M, et al. R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke. Mol Biol Rep. 2012;39:11177–85.CrossRefPubMed
19.
Zurück zum Zitat Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
20.
Zurück zum Zitat Garin MC, James RW, Dussoix P, Blanché H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62–6.CrossRefPubMedPubMedCentral Garin MC, James RW, Dussoix P, Blanché H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62–6.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Viktorinova A, Svitekova K, Stecova A, Krizko M. Relationship between selected oxidative stress markers and lipid risk factors for cardiovascular disease in middle-aged adults and its possible clinical relevance. Clin Biochem. 2016;49:868–72.CrossRefPubMed Viktorinova A, Svitekova K, Stecova A, Krizko M. Relationship between selected oxidative stress markers and lipid risk factors for cardiovascular disease in middle-aged adults and its possible clinical relevance. Clin Biochem. 2016;49:868–72.CrossRefPubMed
22.
Zurück zum Zitat Rizzi F, Conti C, Dogliotti E, Terranegra A, Salvi E, Braga D, et al. Interaction between polyphenols intake and PON1 gene variants on markers of cardiovascular disease: a nutrigenetic observational study. J Transl Med. 2016;14:186.CrossRefPubMedPubMedCentral Rizzi F, Conti C, Dogliotti E, Terranegra A, Salvi E, Braga D, et al. Interaction between polyphenols intake and PON1 gene variants on markers of cardiovascular disease: a nutrigenetic observational study. J Transl Med. 2016;14:186.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Sarkar PD, Shivaprakash TM, Madhusudhan B. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clin Chim Acta. 2006;373:77–81.CrossRefPubMed Sarkar PD, Shivaprakash TM, Madhusudhan B. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clin Chim Acta. 2006;373:77–81.CrossRefPubMed
24.
Zurück zum Zitat Zargari M, Sharafeddin F, Mahrooz A, Alizadeh A, Masoumi P. The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes. Exp Biol Med. 2016;241:1489–96.CrossRef Zargari M, Sharafeddin F, Mahrooz A, Alizadeh A, Masoumi P. The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes. Exp Biol Med. 2016;241:1489–96.CrossRef
25.
Zurück zum Zitat Van den Berg SW, Jansen EH, Kruijshoop M, et al. Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabet Med. 2008;25:186–93.CrossRefPubMed Van den Berg SW, Jansen EH, Kruijshoop M, et al. Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabet Med. 2008;25:186–93.CrossRefPubMed
26.
Zurück zum Zitat Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Brit J Clin Pharmacol. 2008;66:366–74.CrossRef Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Brit J Clin Pharmacol. 2008;66:366–74.CrossRef
27.
Zurück zum Zitat Eckerson HW, Romson J, Wyte CM, la du BN. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35:214–27.PubMedPubMedCentral Eckerson HW, Romson J, Wyte CM, la du BN. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35:214–27.PubMedPubMedCentral
28.
Zurück zum Zitat Patra SK, Singh K, Singh R. Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus. Diabetes Metab Syndr. 2013;7:108–11.CrossRefPubMed Patra SK, Singh K, Singh R. Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus. Diabetes Metab Syndr. 2013;7:108–11.CrossRefPubMed
29.
Zurück zum Zitat Stefanović A, Kotur-Stevuljević J, Vujović A, Spasić S, Spasojević-Kalimanovska V, Jelic-Ivanović Z, et al. Association of the atherogenic index of plasma and oxidative stress status with weight gain during non-complicated pregnancy. Clin Chem Lab Med. 2012;50:2019–25.PubMedCrossRef Stefanović A, Kotur-Stevuljević J, Vujović A, Spasić S, Spasojević-Kalimanovska V, Jelic-Ivanović Z, et al. Association of the atherogenic index of plasma and oxidative stress status with weight gain during non-complicated pregnancy. Clin Chem Lab Med. 2012;50:2019–25.PubMedCrossRef
30.
Zurück zum Zitat Aydin M, Gencer M, Cetinkaya Y, Ozkok E, Ozbek Z, Kilic G, et al. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life. 2006;58:165–72.CrossRefPubMed Aydin M, Gencer M, Cetinkaya Y, Ozkok E, Ozbek Z, Kilic G, et al. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life. 2006;58:165–72.CrossRefPubMed
31.
Zurück zum Zitat Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–76.CrossRefPubMed Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–76.CrossRefPubMed
32.
Zurück zum Zitat Aviram M, Billeke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617–24.CrossRefPubMed Aviram M, Billeke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617–24.CrossRefPubMed
33.
Zurück zum Zitat Barbieri M, Bonafè M, Marfella R, Ragno E, Giugliano D, Franceschi C, et al. LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J Clin Endocrinol Metab. 2002;87:222–5.CrossRefPubMed Barbieri M, Bonafè M, Marfella R, Ragno E, Giugliano D, Franceschi C, et al. LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J Clin Endocrinol Metab. 2002;87:222–5.CrossRefPubMed
34.
Zurück zum Zitat Rios DL, D'Onofrio LO, Cerqueira C, Bonfim-Silva R, Carvalho HG, Santos-Filho A, et al. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. Clin Chem Lab Med. 2007;45:874–8.CrossRefPubMed Rios DL, D'Onofrio LO, Cerqueira C, Bonfim-Silva R, Carvalho HG, Santos-Filho A, et al. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. Clin Chem Lab Med. 2007;45:874–8.CrossRefPubMed
Metadaten
Titel
Genotype and phenotype of salt-stimulated paraoxonase 1 (PON1) is associated with atherogenic indices in type 2 diabetes
verfasst von
Durdi Qujeq
Abdolkarim Mahrooz
Ahad Alizadeh
Parisa Masoumi
Saleh Annemohammadzadeh
Ruzbeh Boorank
Publikationsdatum
26.03.2018
Verlag
Springer International Publishing
Erschienen in
Journal of Diabetes & Metabolic Disorders / Ausgabe 1/2018
Elektronische ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-018-0332-z

Weitere Artikel der Ausgabe 1/2018

Journal of Diabetes & Metabolic Disorders 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.